Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia
- PMID: 40365252
- PMCID: PMC12068484
- DOI: 10.1093/skinhd/vzaf009
Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia
Abstract
Androgenetic alopecia (AGA) is a hair disorder seen in both sexes. Its aetiology is multifactorial. Treating AGA has always been a challenge for dermatologists. Only a few drugs such as topical minoxidil and finasteride are U.S. Food and Drug Administration-approved for treating AGA. Thus, looking for new and more effective treatment options for AGA is imperative. This review was conducted to compare the efficacy of oral with topical minoxidil in treating AGA. Only clinical trials that compared oral with topical minoxidil in treating AGA were included in this review. PubMed, Cochrane, Scopus and ClinicalTrials.gov were searched. A total of 2063 studies were retrieved from the databases. Four studies met the inclusion criteria and were included in this systematic review. Outcomes such as hair density, terminal hair density, hair count, global photographic assessment and negative hair pull were studied in this review. The results showed that there was no significant difference between oral and topical minoxidil in terms of improving the hair density of patients with AGA (overall mean difference 0.95, 95% confidence interval -24.98 to 26.87). Two studies showed that the mean difference in terminal hair density was greater in patients treated with oral minoxidil, but there was no significant difference between the two treatments in terms of improving terminal hair density. The efficacy of oral minoxidil is comparable to that of topical minoxidil in terms of improving hair density and terminal hair density in patients with AGA. Oral minoxidil can be used as an adjunct or as a second-line treatment option for AGA.
© The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists.
Conflict of interest statement
Conflicts of interest: The authors declare no conflicts of interest.
Figures




Similar articles
-
Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.JAMA Dermatol. 2024 Jun 1;160(6):600-605. doi: 10.1001/jamadermatol.2024.0284. JAMA Dermatol. 2024. PMID: 38598226 Free PMC article. Clinical Trial.
-
Androgenetic alopecia: an evidence-based treatment update.Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. Am J Clin Dermatol. 2014. PMID: 24848508 Review.
-
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia.J Drugs Dermatol. 2023 Sep 1;22(9):905-909. doi: 10.36849/JDD.7031. J Drugs Dermatol. 2023. PMID: 37683060 Clinical Trial.
-
Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia.Expert Opin Pharmacother. 2024 Feb;25(2):139-147. doi: 10.1080/14656566.2024.2314087. Epub 2024 Feb 6. Expert Opin Pharmacother. 2024. PMID: 38315101 Review.
-
The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis.Aesthetic Plast Surg. 2020 Jun;44(3):962-970. doi: 10.1007/s00266-020-01621-5. Epub 2020 Mar 12. Aesthetic Plast Surg. 2020. PMID: 32166351
References
-
- Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002; 37:981–90. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous